心肌梗死非罪犯病变的即时或延迟PCI
该国际、研究者发起的开放标签随机对照试验纳入1146例STEMI且至少一处非罪犯病变、已成功行直接PCI的患者,1:1随机分为即时iFR指导PCI组(病变狭窄>50%且iFR≤0.89)或随机后6周内延迟心脏负荷MRI指导PCI组。主要终点为3年随访全因死亡、再发心肌梗死或心衰住院的复合终点。iFR组50例(9.3%)发生主要终点事件,MRI组55例(9.8%),HR 0.95(95%CI 0.65-1.40,P=0.81),即时iFR指导PCI不优于延迟MRI指导PCI。
要点
- STEMI成功直接PCI后,非罪犯病变即时iFR指导PCI组3年主要终点事件9.3%(50例),延迟心脏负荷MRI指导PCI组9.8%(55例),HR 0.95(95%CI 0.65-1.40,P=0.81)。
- 即时iFR组非罪犯病变PCI实施率42.6%(237/556),延迟MRI组18.7%(110/587)。
- 严重不良事件iFR组145例,MRI组181例。
- 即时iFR指导PCI在3年死亡、再发心梗或心衰住院复合终点上不优于延迟心脏负荷MRI指导PCI。
适用人群与场景
- STEMI且至少一处非罪犯病变、已成功行直接PCI的患者;平均年龄63±11岁,78%为男性。
诊断标准与关键阈值
- 即时iFR指导PCI组:非罪犯病变狭窄>50%且iFR≤0.89(正常值>0.89)时行PCI。
- 延迟组:随机后6周内行心脏负荷MRI指导的PCI。
处置流程与药物剂量
- 即时iFR指导PCI组:对狭窄>50%且iFR≤0.89的非罪犯病变行PCI。
- 延迟组:随机后6周内行心脏负荷MRI指导的PCI。
研究设计与关键结果
- 国际、研究者发起、开放标签、随机对照试验,纳入1146例患者(iFR组558例,MRI组588例)。
- 非罪犯病变PCI实施率:iFR组42.6%(237/556)vs MRI组18.7%(110/587)。
- 3年主要终点(全因死亡、再发心梗或心衰住院复合终点):iFR组9.3%(50例)vs MRI组9.8%(55例),HR 0.95(95%CI 0.65-1.40,P=0.81)。
- 严重不良事件:iFR组145例 vs MRI组181例。
证据类型、等级与局限
- 证据类型:国际、研究者发起、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于STEMI成功行直接PCI且存在非罪犯病变的患者,即时iFR指导PCI在3年死亡、再发心梗或心衰住院复合终点上不优于延迟心脏负荷MRI指导PCI。
指南或共识出处
- iMODERN试验(ClinicalTrials.gov NCT03298659),由Philips Volcano等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. A comparison of immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease is warranted.
METHODS: In this international, investigator-initiated, open-label, randomized, controlled trial, patients with STEMI and at least one nonculprit lesion who had undergone successful primary PCI were randomly assigned in a 1:1 ratio to immediate iFR-guided PCI (in lesions with >50% stenosis and an iFR of ≤0.89 [normal value, >0.89]) or deferred cardiac stress MRI-guided PCI within 6 weeks after randomization. The primary end point was a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure at 3-year follow-up.
RESULTS: The trial included 1146 patients (558 in the iFR group and 588 in the MRI group) with a mean (±SD) age of 63±11 years; 78% were men. A total of 237 of 556 patients (42.6%) in the iFR group and 110 of 587 patients (18.7%) in the MRI group underwent nonculprit-lesion coronary-artery PCI. A primary-end-point event occurred in 50 patients (9.3%) in the iFR group and in 55 patients (9.8%) in the MRI group (hazard ratio, 0.95; 95% confidence interval, 0.65 to 1.40; P = 0.81). Serious adverse events occurred in 145 patients in the iFR group and in 181 in the MRI group.
CONCLUSIONS: Among patients with STEMI who have undergone successful primary PCI, immediate iFR-guided PCI was not superior to deferred cardiac stress MRI-guided PCI of nonculprit coronary-artery lesions with respect to death from any cause, recurrent myocardial infarction, or hospitalization for heart failure at 3 years. (Funded by Philips Volcano and others; iMODERN ClinicalTrials.gov number, NCT03298659.).
参考来源
- Nijveldt R, Maeng M, Beijnink CWH, et al. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. 2025. PMID: 41159879. doi:10.1056/NEJMoa2512918
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。